Novacyt S.A. Liquidity Agreement Update and Total Voting Rights (5360Y)
02 Enero 2020 - 4:30AM
UK Regulatory
TIDMNCYT
RNS Number : 5360Y
Novacyt S.A.
02 January 2020
Liquidity Agreement Monthly Update and
Total Voting Rights
Paris, France and Camberley, UK - 2 January 2020 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces its monthly update in
relation to ordinary shares traded under its ongoing liquidity
agreement with Invest Securities SA (the "Liquidity Agreement").
The Liquidity Agreement is governed by French law and is further
summarised in the 'notes for editors' section below.
During the period from 1 December to 31 December 2019, Invest
Securities purchased 25,003 ordinary shares at a maximum price of
EUR0.15 and a minimum price of EUR0.12 and sold 17,003 ordinary
shares at a maximum price of EUR0.16 and a minimum price of EUR0.12
under the Liquidity Agreement. The total number of ordinary shares
in the Company, which are held in treasury as at close of business
on 31 December 2019, is 64,016.
Total Voting Rights
The total number of ordinary shares in the Company is
58,094,754. This figure may be used by shareholders as the
denominator for calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not
subject to the disclosure guidance and transparency rules made by
the Financial Conduct Authority under Part VI of FSMA.
For further information, please refer to www.novacyt.com or
contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves oncology,
microbiology, haematology and serology markets as do its global
partners, which include major corporates.
Further information on the Liquidity Agreement
On 12 September 2016, the Company and Invest Securities entered
into the Liquidity Agreement pursuant to which Invest Securities
provides liquidity services in relation to the ordinary shares to
the Company. Invest Securities may purchase ordinary shares on
behalf of the Company under the agreement, subject to approval from
Shareholders as to the price at which ordinary shares can be
brought back and the aggregate amount that the Company may provide
to Invest Securities to purchase such ordinary shares.
Shareholder approval was granted at the Shareholders' meeting
held on 27 June 2017 for the purchase of ordinary shares by Invest
Securities under the agreement at a maximum purchase price per
ordinary shares of EUR8.10 for an aggregate maximum purchase price
of EUR100,000 and for 18 months from the date of the approval.
Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate
with the employees of Invest Securities who are responsible for
performing the agreement. Invest Securities is paid EUR10,000 per
annum for its services under the liquidity agreement. The agreement
has an initial term of two years, with a rolling extension of one
year thereafter. The agreement can be terminated by either party at
the end of each such period subject to two months' prior notice.
The Liquidity Agreement is governed by French law. Ordinary shares
purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for
dividends).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKKBBQCBKKODK
(END) Dow Jones Newswires
January 02, 2020 05:30 ET (10:30 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024